Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Sells $3,769,800.30 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 40,985 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the transaction, the chief executive officer owned 194,309 shares in the company, valued at $17,872,541.82. This represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Monday, February 2nd, Christopher Peetz sold 9,108 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $103.30, for a total transaction of $940,856.40.
• On Monday, January 26th, Christopher Peetz sold 6,831 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total transaction of $657,073.89.
• On Thursday, January 22nd, Christopher Peetz sold 7,098 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $662,456.34.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $90.72 on Friday. The business’s 50 day moving average price is $96.51 and its two-hundred day moving average price is $81.14. The company has a market cap of $5.47 billion, a PE ratio of -189.00 and a beta of 0.52. The company has a quick ratio of 2.55, a current ratio of 2.67 and a debt-to-equity ratio of 0.98. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.88 and a twelve month high of $109.28.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The business had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. During the same period in the previous year, the business earned $1.00 earnings per share. The business’s quarterly revenue was up 49.8% on a year-over-year basis. On average, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Comerica Bank lifted its holdings in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after buying an additional 278 shares in the last quarter. AQR Capital Management LLC grew its stake in shares of Mirum Pharmaceuticals by 307.3% in the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after acquiring an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after acquiring an additional 1,720 shares during the period. Caxton Associates LLP bought a new position in Mirum Pharmaceuticals during the first quarter worth about $217,000. Finally, Empowered Funds LLC raised its stake in Mirum Pharmaceuticals by 15.4% in the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after purchasing an additional 5,120 shares in the last quarter.

Analysts Set New Price Targets

MIRM has been the subject of several research reports. Evercore set a $126.00 price target on Mirum Pharmaceuticals in a report on Wednesday, March 4th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. Leerink Partners cut their target price on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Finally, Citizens Jmp decreased their price target on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $117.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.